Tesseract Health reports it has raised $80 million in an oversubscribed Series B financing round to advance the development of its Tesseract iC eye-imaging diagnostic technology platform.
According to the company, the platform will use retinal imaging to diagnose a range of human diseases and health issues. The company says recent advances in artificial intelligence have enabled “accurate prediction of a person’s blood pressure, diabetic risk, smoking history, Alzheimer’s progression and heart attack risk by peering into the eye with a camera and an algorithm.”